Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All remdesivir studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchRemdesivirRemdesivir (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Paxlovid Meta
Famotidine Meta Quercetin Meta
Favipiravir Meta Remdesivir Meta
Fluvoxamine Meta Thermotherapy Meta
Hydroxychlor.. Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Efficacy and Safety of Remdesivir for COVID-19 Treatment: An Analysis of Randomized, Double-Blind, Placebo-Controlled Trials

Zhu et al., medRxiv, doi:10.1101/2020.06.22.20136531
Jun 2020  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Mortality 36% Improvement Relative Risk Remdesivir for COVID-19  Zhu et al.  META ANALYSIS c19early.org Favorsremdesivir Favorscontrol 0 0.5 1 1.5 2+
Meta analysis of Beigel and Wang RCTs showing remdesivir significantly decreased mortality (8.18% vs. 12.70%, RR 0.64 [0.44-0.92], p = 0.175).
Currently there are 73 remdesivir studies and meta analysis shows:
OutcomeImprovement
Mortality3% lower [-6‑11%]
Ventilation18% higher [-13‑60%]
ICU admission119% higher [33‑259%]
Hospitalization8% higher [-12‑33%]
risk of death, 36.0% lower, RR 0.64, p = 0.02.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Zhu et al., 29 Jun 2020, preprint, 11 authors.
This PaperRemdesivirAll
Efficacy and Safety of Remdesivir for COVID-19 Treatment: An Analysis of Randomized, Double-Blind, Placebo-Controlled Trials
Yun Zhu, M.D Zhaowei Teng, Ph.D Lirong Yang, Ph.D Shuanglan Xu, M.D Jie Liu, M.D Yirong Teng, M.D Qinggang Hao, M.D Dake Zhao, Xiaolan Xiaolan Li, M.D Sheng Lu, M.D Yong Zeng
doi:10.1101/2020.06.22.20136531
BACKGROUND Remdesivir, an inhibitor of viral RNA-dependent RNA polymerases, has been identified as a candidate for COVID-19 treatment. However, the therapeutic effect of remdesivir is controversial. METHODS We searched PubMed, Embase, and the Cochrane Central Register of Controlled Trials, from inception to June 11, 2020 for randomized controlled trials on the clinical efficacy of remdesivir. The main outcomes were discharge rate, mortality, and adverse events. This study is registered at INPLASY (INPLASY202060046). RESULTS Data of 1075 subjects showed that remdesivir significantly increased the discharge rate of patients with COVID-19 compared with the placebo (50.4% vs. 45.29%; relative risk [RR] 1.19 [95% confidence interval [CI], 1.05-1.34], I 2 = 0.0%, P = 0.754). It also significantly decreased mortality (8.18% vs. 12.70%; RR 0.64 [95% CI, 0.44-0.92], I 2 = 45.7%, P = 0.175) compared to the placebo. Data of 1296 subjects showed that remdesivir significantly decreased the occurrence of serious adverse events (RR 0.77 [95% CI, 0.63-0.94], I 2 = 0.0%, P = 0.716). CONCLUSION Remdesivir is efficacious and safe for the treatment of COVID-19. TRIAL REGISTRATION NUMBER 2 .
Efficacy and Safety of
References
Beigel, Tomashek, Dodd, Remdesivir for the treatment of Covid-19 -preliminary report, N Engl J Med, doi:10.1056/NEJMoa2007764
Bhatraju, Ghassemieh, Nichols, Covid-19 in critically ill patients in the Seattle region -case series, N Engl J Med
Dersimonian, Laird, Meta-analysis in clinical trials, Control Clin Trials
Eastman, Roth, Brimacombe, Remdesivir: A review of its discovery and development leading to emergency use authorization for treatment of COVID-19, ACS Cent Sci
Goldman, Lye, Hui, Remdesivir for 5 or 10 days in patients with severe Covid-19, N Engl J Med, doi:10.1056/NEJMoa2015301
Grein, Ohmagari, Shin, Compassionate use of remdesivir for patients with severe Covid-19, N Engl J Med
Higgins, Thompson, Deeks, Measuring inconsistency in meta-analyses, BMJ
Holshue, Debolt, Lindquist, First case of 2019 novel coronavirus in the United States, N Engl J Med
Jadad, Moore, Carroll, Assessing the quality of reports of randomised clinical trials: is blinding necessary?, Control Clin Trials
Mahase, Covid-19: Remdesivir is helpful but not a wonder drug, say researchers, BMJ
Or, )) OR (Novel coronavirus pneumonia)
Patel, Jernigan, Ncdcr, Initial public health response and interim clinical guidance for the 2019 novel coronavirus outbreak -United States, December 31, 2019-February 4, 2020, Am J Transplant
Sheahan, Sims, Graham, Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses, Sci Transl Med
Sheahan, Sims, Leist, Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV, Nat Commun
Wang, Cao, Zhang, Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell Res
Wang, Zhang, Du, Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial, Lancet
Williamson, Feldmann, Schwarz, Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2, Nature, doi:10.1038/s41586-020-2423-5
Woolf, On estimating the relation between blood group and disease, Ann Hum Genet
Zhou, Yu, Du, Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet
Zhu, Zhang, Wang, A novel coronavirus from patients with pneumonia in China, 2019, N Engl J Med
{ 'institution': [{'name': 'medRxiv'}], 'indexed': {'date-parts': [[2024, 3, 12]], 'date-time': '2024-03-12T12:21:28Z', 'timestamp': 1710246088757}, 'posted': {'date-parts': [[2020, 6, 29]]}, 'group-title': 'Epidemiology', 'reference-count': 19, 'publisher': 'Cold Spring Harbor Laboratory', 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'accepted': {'date-parts': [[2020, 6, 29]]}, 'abstract': '<jats:title>Abstract</jats:title><jats:sec><jats:title>BACKGROUND</jats:title><jats:p>Remdesivir, ' 'an inhibitor of viral RNA-dependent RNA polymerases, has been identified as a candidate for ' 'COVID-19 treatment. However, the therapeutic effect of remdesivir is ' 'controversial.</jats:p></jats:sec><jats:sec><jats:title>METHODS</jats:title><jats:p>We ' 'searched PubMed, Embase, and the Cochrane Central Register of Controlled Trials, from ' 'inception to June 11, 2020 for randomized controlled trials on the clinical efficacy of ' 'remdesivir. The main outcomes were discharge rate, mortality, and adverse events. This study ' 'is registered at INPLASY ' '(INPLASY202060046).</jats:p></jats:sec><jats:sec><jats:title>RESULTS</jats:title><jats:p>Data ' 'of 1075 subjects showed that remdesivir significantly increased the discharge rate of ' 'patients with COVID-19 compared with the placebo (50.4% vs. 45.29%; relative risk [RR] 1.19 ' '[95% confidence interval [CI], 1.05–1.34], I<jats:sup>2</jats:sup> = 0.0%, P = 0.754). It ' 'also significantly decreased mortality (8.18% vs. 12.70%; RR 0.64 [95% CI, 0.44–0.92], ' 'I<jats:sup>2</jats:sup> = 45.7%, P = 0.175) compared to the placebo. Data of 1296 subjects ' 'showed that remdesivir significantly decreased the occurrence of serious adverse events (RR ' '0.77 [95% CI, 0.63–0.94], I<jats:sup>2</jats:sup> = 0.0%, P = ' '0.716).</jats:p></jats:sec><jats:sec><jats:title>CONCLUSION</jats:title><jats:p>Remdesivir is ' 'efficacious and safe for the treatment of ' 'COVID-19.</jats:p></jats:sec><jats:sec><jats:title>TRIAL REGISTRATION ' 'NUMBER</jats:title><jats:p>This study is registered at the International Platform of ' 'Registered Systematic Review and Meta-analysis Protocols ' '(INPLASY202060046).</jats:p></jats:sec>', 'DOI': '10.1101/2020.06.22.20136531', 'type': 'posted-content', 'created': {'date-parts': [[2020, 6, 29]], 'date-time': '2020-06-29T20:15:13Z', 'timestamp': 1593461713000}, 'source': 'Crossref', 'is-referenced-by-count': 2, 'title': 'Efficacy and Safety of Remdesivir for COVID-19 Treatment: An Analysis of Randomized, ' 'Double-Blind, Placebo-Controlled Trials', 'prefix': '10.1101', 'author': [ {'given': 'Yun', 'family': 'Zhu', 'sequence': 'first', 'affiliation': []}, {'given': 'Zhaowei', 'family': 'Teng', 'sequence': 'additional', 'affiliation': []}, {'given': 'Lirong', 'family': 'Yang', 'sequence': 'additional', 'affiliation': []}, {'given': 'Shuanglan', 'family': 'Xu', 'sequence': 'additional', 'affiliation': []}, {'given': 'Jie', 'family': 'Liu', 'sequence': 'additional', 'affiliation': []}, {'given': 'Yirong', 'family': 'Teng', 'sequence': 'additional', 'affiliation': []}, {'given': 'Qinggang', 'family': 'Hao', 'sequence': 'additional', 'affiliation': []}, {'given': 'Dake', 'family': 'Zhao', 'sequence': 'additional', 'affiliation': []}, {'given': 'Xiaolan', 'family': 'Li', 'sequence': 'additional', 'affiliation': []}, {'given': 'Sheng', 'family': 'Lu', 'sequence': 'additional', 'affiliation': []}, {'given': 'Yong', 'family': 'Zeng', 'sequence': 'additional', 'affiliation': []}], 'member': '246', 'reference': [ { 'key': '2021010507151271000_2020.06.22.20136531v1.1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/S0140-6736(20)30566-3'}, { 'key': '2021010507151271000_2020.06.22.20136531v1.2', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMoa2001017'}, { 'key': '2021010507151271000_2020.06.22.20136531v1.3', 'doi-asserted-by': 'crossref', 'first-page': '889', 'DOI': '10.1111/ajt.15805', 'article-title': 'Team nCDCR. Initial public health response and interim clinical ' 'guidance for the 2019 novel coronavirus outbreak - United States, ' 'December 31, 2019-February 4, 2020', 'volume': '20', 'year': '2020', 'journal-title': 'Am J Transplant'}, { 'key': '2021010507151271000_2020.06.22.20136531v1.4', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41467-019-13940-6'}, { 'key': '2021010507151271000_2020.06.22.20136531v1.5', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41422-020-0282-0'}, { 'key': '2021010507151271000_2020.06.22.20136531v1.6', 'doi-asserted-by': 'publisher', 'DOI': '10.1126/scitranslmed.aal3653'}, { 'key': '2021010507151271000_2020.06.22.20136531v1.7', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/S0140-6736(20)31022-9'}, { 'key': '2021010507151271000_2020.06.22.20136531v1.8', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMoa2007764'}, { 'key': '2021010507151271000_2020.06.22.20136531v1.9', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMoa2015301'}, { 'key': '2021010507151271000_2020.06.22.20136531v1.10', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NE-JMoa2007016'}, { 'key': '2021010507151271000_2020.06.22.20136531v1.11', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/0197-2456(95)00134-4'}, { 'key': '2021010507151271000_2020.06.22.20136531v1.12', 'doi-asserted-by': 'publisher', 'DOI': '10.1136/bmj.327.7414.557'}, { 'key': '2021010507151271000_2020.06.22.20136531v1.13', 'doi-asserted-by': 'publisher', 'DOI': '10.1111/j.1469-1809.1955.tb01348.x'}, { 'key': '2021010507151271000_2020.06.22.20136531v1.14', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/0197-2456(86)90046-2'}, { 'key': '2021010507151271000_2020.06.22.20136531v1.15', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41586-020-2423-5'}, { 'key': '2021010507151271000_2020.06.22.20136531v1.16', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMoa2004500'}, { 'key': '2021010507151271000_2020.06.22.20136531v1.17', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMoa2001191'}, { 'key': '2021010507151271000_2020.06.22.20136531v1.18', 'doi-asserted-by': 'crossref', 'first-page': '672', 'DOI': '10.1021/acscentsci.0c00489', 'article-title': 'Remdesivir: A review of its discovery and development leading to ' 'emergency use authorization for treatment of COVID-19', 'volume': '6', 'year': '2020', 'journal-title': 'ACS Cent Sci'}, { 'key': '2021010507151271000_2020.06.22.20136531v1.19', 'doi-asserted-by': 'publisher', 'DOI': '10.1136/bmj.m1798'}], 'container-title': [], 'original-title': [], 'link': [ { 'URL': 'https://syndication.highwire.org/content/doi/10.1101/2020.06.22.20136531', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2021, 1, 5]], 'date-time': '2021-01-05T22:27:20Z', 'timestamp': 1609885640000}, 'score': 1, 'resource': {'primary': {'URL': 'http://medrxiv.org/lookup/doi/10.1101/2020.06.22.20136531'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2020, 6, 29]]}, 'references-count': 19, 'URL': 'http://dx.doi.org/10.1101/2020.06.22.20136531', 'relation': {}, 'subject': [], 'published': {'date-parts': [[2020, 6, 29]]}, 'subtype': 'preprint'}
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit